In a study reported in the Journal of Clinical Oncology, Jennifer L. Beebe-Dimmer, MPH, PhD, and colleagues found that the risk of prostate cancer varied according to cancer family history, with the strongest association being observed between family history and early-onset prostate cancer.
In an Australian phase III trial reported in The Lancet, Michael S. Hofman, MBBS, and colleagues found that gallium-68 prostate-specific membrane antigen-11 positron-emission tomography/computed tomography (PSMA PET/CT) provided greater accuracy in identifying nodal and distant metastases vs conventional imaging with CT and bone scanning prior to curative-intent surgery or radiotherapy in men with high-risk prostate cancer.
In a phase II trial reported in JAMA Oncology, Ryan Phillips, MD, PhD, and colleagues found that stereotactic ablative radiotherapy was associated with improved outcomes vs observation in men with oligometastatic prostate cancer.
In an analysis from the NRG/RTOG 9601 trial reported in JAMA Oncology, Daniel E. Spratt, MD, and colleagues found that higher prostate-specific antigen (PSA) pre–salvage radiotherapy levels after prostatectomy were associated with better overall survival vs lower levels in men with prostate cancer receiving long-term antiandrogen therapy.
Although patients with metastatic castration-resistant prostate cancer typically have limited responses to immunotherapy, a subset of patients with pretreatment evidence of active T-cell responses in their tumors experienced prolonged survival following treatment with ipilimumab in a phase II trial. These findings were published by Sumit K. Subudhi, MD, PhD, and colleagues in Science Translational Medicine.